Axios · Natalie Breymeyer ·

Mithrl, which integrates its proprietary biomedical world model with the R&D systems of pharmaceutical companies, raised a $20M Series A led by Obvious Ventures

Mithrl, an AI infrastructure company for biopharma, raised a $20 million Series A, CEO Vivek Adarsh tells Axios exclusively.

Venture Capital

In this story Mithrl Obvious Ventures

Mithrl, which integrates its proprietary biomedical world model with the R&D systems of pharmaceutical companies, raised a $20M Series A led by Obvious Ventures

Lead Source

Axios — Mithrl, which integrates its proprietary biomedical world model with the R&D systems of pharmaceutical companies, raised a $20M Series A led by Obvious Ventures ↗

How this story grew

Coverage · 0 Discussion · 0

Sep 21Sep 22

More

Dealroom.co: Dealroom.co

GEN: GEN

Mithrl: Mithrl

WOWTALE: WOWTALE

Mithrl: Mithrl

The SaaS News: The SaaS News

FinSMEs: FinSMEs

Discussion

Related stories

Dealroom.co: Faro, which develops data models and AI tools to speed up clinical trials, raised a $37.3M Series B co-led by Merck Global Health Innovation Fund and S32

Bloomberg: Mirendil, founded by former Anthropic researchers to build self-improving AI, is in talks to raise ~$1B led by Kleiner Perkins at a $5B valuation

GamesBeat: Astromech, which uses genomic data to build predictive AI models of biological change, raised $20M at a $3.8B valuation, bringing its total funding to $60M

Wall Street Journal: Network Bio, which is developing an AI foundation model from datasets of patient tissue and blood samples created by pooling access to biobanks, raised $50M

Axios: Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, raised a $25M Series A

Discuss with AI

ChatGPT ↗ Claude ↗

← Back to TechSnif